Clinical TrialsDRMA announced positive topline results from its first pivotal Phase 3 trial of XYNGARI, achieving all primary endpoints with statistically significant differences compared to placebo.
Financial HealthDRMA has no debt and sufficient liquidity to last into the second quarter of 2025, which supports its ongoing development activities.
Patient ComplianceThe unique once-weekly application of XYNGARI could improve patient compliance compared to current FDA-approved topicals that require daily application.